Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain

A systematic review: Cost‐effectiveness of continuous glucose monitoring compared to self‐monitoring of blood glucose in type 1 diabetes

“…These studies assessed cost‐effectiveness from the viewpoint of 11 countries. With regards to the associated treatment, seven studies compared continuous subcutaneous insulin infusion (CSII) and SMBG versus sensor‐augmented pump (SAP) 12–18,25 . Four studies 19–22 assessed CGM versus SMBG in the context of multiple daily injections (MDI); two studies compared MDI and SMBG with SAP 23,24 ; three studies assessed SMBG with MDI or CSII in comparison with hybrid closed‐loop systems (HCL) 25–27 and three studies 28–30 compared CGM and SMBG regardless of the mode of insulin delivery.…”

“…Input relating to HbA1c reduction were sourced from nine different studies and had results that ranged from 0.23% to 1.5% reduction. In one study the source of HbA1C reduction could not be identified 16 . FoH score improvements ranged from 2.3 to 9.25‐points with use of CGM compared to SMBG.…”

“…details the cost‐effectiveness of CGM in the form of ICER. The seven studies 12–18,25 which compared CSII and SMBG versus SAP and reported a QALY gain within the range of [0.76–2.99] and ICER range of [$18,734–$99,941]. Studies assessing CGM versus SMBG ( n = 4) in context of MDI reported QALY and ICER gain with the range of [0.54–3.35] and [$19,961– $149,634] respectively.…”

Cost-effectiveness of real time continuous glucose monitoring to target glucose control in preterm infants

“…Previous economic evaluations of real time CGM were conducted in clinical contexts outside of neonatal intensive care and therefore, a comparative assessment of costeffectiveness evidence is not possible. [40][41][42] Moreover, prior to REACT, previous studies of real time CGM in infants had been restricted to a small number of extremely preterm infants. 9,43 Our data should, therefore, be of relevance to clinical decision-makers and service planners tasked with preventing the adverse sequelae of hyperglycemia, hypoglycemia, and glycaemic instability in preterm infants.…”

Continuous Glucose Monitoring in 2018

“…Another company-sponsored national analysis (using the CORE model) in Spain estimated the incremental costeffectiveness ratio for the use of sensor-augmented pumps of e25,394/QALY (19), which is below the Spanish national insurance threshold for reimbursement. Finally, a more affordable variant-the intermittent glucose monitoring or ''Flash'' glucose monitoring-received public reimbursement in several countries in the European Union (including the United Kingdom) and the United States (20).…”